Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Bristol Myers Squibb and AstraZeneca are reportedly in talks regarding a potential mega-merger that would create the largest pharmaceutical company in history, though analysts remain skeptical due to significant antitrust concerns and potential product overlap in oncology. Meanwhile, the pharmaceutical industry navigat...
Arvinas CEO Randy Teel details the strategic pivot from a late-stage commercial focus to an early-stage, platform-driven pipeline. Following the FDA approval and subsequent outlicensing of their lead asset, the company reallocated capital toward Phase 1 programs in oncology and neurology. Success during such inflection...
FDA advisory committee meetings are dominating the biopharma landscape, with the agency challenging the trial data for Capricor’s Duchenne muscular dystrophy therapy and questioning the sufficiency of Replimune’s single-arm study for melanoma. Meanwhile, the second-quarter earnings season is underway, highlighted by GS...
The Nordic biotech landscape reveals a significant divergence between Denmark’s thriving ecosystem and the structural hurdles facing Sweden, Norway, and Finland. Denmark’s success stems from a unique foundation-led model, exemplified by the Novo Nordisk Foundation and the BioInnovation Institute, which provides long-te...
The biopharma industry enters a busy second-quarter earnings season, with major players like AbbVie, Amgen, and Eli Lilly under scrutiny for their recent acquisitions and product launches. Eli Lilly’s multi-billion dollar investment in Atai Life Sciences signals significant validation for the psychedelic medicine secto...
The biotech industry is experiencing significant shifts following data readouts from the Alzheimer’s Association International Conference and recent clinical trial results. Biogen’s anti-tau therapy, daranirsen, demonstrated potential in slowing Alzheimer’s progression, while the FDA’s approval of a subcutaneous, at-ho...
Cell line development serves as the foundational decision in biologics manufacturing, dictating the long-term efficiency and cost-effectiveness of drug production. CHO (Chinese Hamster Ovary) cells remain the industry standard due to their robust growth, regulatory acceptance, and human-like glycosylation patterns. Mod...
The biopharma industry experienced significant activity in the first half of 2024, highlighted by Vertex’s $10 billion acquisition of Cryonetics Pharmaceuticals, a major move in the endocrinology space. M&A activity remains robust, with companies like Novartis, Gilead, and GSK actively pursuing deals, though Eli Lilly ...
Biopharma M&A activity remains robust, highlighted by AbbVie’s $10.9 billion acquisition of Apogee Therapeutics to bolster its immunology pipeline and address patent cliffs. Regulatory landscapes are shifting, with the FDA reversing previous stances on gene therapies from uniQure and REGENXBIO, signaling a potential mo...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
